ArticleiScience2023
Ca-EDTA restores the activity of ceftazidime-avibactam or aztreonam against carbapenemase-producing
Article in iScience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 18 citations in OpenAlex.
- Real-World Effectiveness of Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Pneumonia, Time-Stratified Risk Factors for Short- and Long-Term Mortality, and Inpatient Costs: A Multicenter Retrospective Cohort Study.Infectious diseases and therapy · 2026Article
- Emerging therapeutic drug targets in amino acid and protein biosynthesis pathways against ESKAPE and non-ESKAPE pathogens: a comprehensive review.Archives of microbiology · 2026Review
- tesG expression as a potential clinical biomarker for chronic Pseudomonas aeruginosa pulmonary biofilm infections.BMC medicine · 2025Article
- Clinical, antibiotic resistance features, and treatment outcomes of Vietnamese patients with community-acquired sepsis caused byIJID regions · 2025Article
- First detection of multidrug-resistant and toxigenic Pasteurella aerogenes in sow vaginal discharge: a novel threat to swine health in Thailand.Scientific reports · 2024Article
- Evaluation of mrkD, pgaC and wcaJ as biomarkers for rapid identification of K. pneumoniae biofilm infections from endotracheal aspirates and bronchoalveolar lavage.Scientific reports · 2024Article
- Respiratory carriage of hypervirulent Klebsiella pneumoniae by indigenous populations of Malaysia.BMC genomics · 2024Article
- Monitoring ofInfection and drug resistance · 2024Article
- Combination of aloe emodin, emodin, and rhein from Aloe with EDTA sensitizes the resistantFrontiers in cellular and infection microbiology · 2024Article
- Ceftazidime-Avibactam Combination Therapy versus Monotherapy for the Treatment Carbapenem-Resistant Gram-Negative Bacterial Infections: A Retrospective Observational Study.Infection and drug resistance · 2024Article
- Interactions and Implications ofInfection and drug resistance · 2024Review
- Clinical Efficacy and Safety Evaluation of Ceftazidime-Avibactam in the Treatment ofInfection and drug resistance · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors at 18 institutions in 9 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Developing an effective therapy to overcome carbapenemase-positive
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.